Martin-Broto, Javier
Valverde, Claudia
Hindi, Nadia
Vincenzi, Bruno
Martinez-Trufero, Javier
Grignani, Giovanni
Italiano, Antoine
Lavernia, Javier
Vallejo, Ana
Tos, Paolo Dei
Le Loarer, Francois
Gonzalez-Campora, Ricardo
Ramos, Rafael
Hernández-Jover, Diana
Gutierrez, Antonio
Serrano, Cesar
Monteagudo, Maria
Letón, Rocio
Robledo, Mercedes
Moura, David S.
Martin-Ruiz, Marta
López-Guerrero, Jose A.
Cruz, Julia
Fernandez-Serra, Antonio
Blay, Jean-Yves
Fumagalli, Elena
Martinez-Marin, Virginia
Funding for this research was provided by:
Spanish group for research on Sarcoma
Bayer
European Union’s Horizon 2020 research and innovation program (825806)
Article History
Received: 8 June 2023
Accepted: 26 July 2023
First Online: 9 August 2023
Declarations
:
: Approval from the ethics committee of each participating center was obtained before study initiation.
: Not applicable.
: Javier Martin-Broto reports research grants from PharmaMar, Eisai, Immix BioPharma and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, Eli Lilly and Company, Bayer, GSK, Novartis, Boehringer Ingelheim, Amgen, Roche, Tecnofarma and Asofarma; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, BMS, Pfizer, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Celgene, Novartis, Blueprint, Adaptinmune, Nektar, Forma, Amgen, Daichii-Sankyo, Ran Therapeutics, INHIBRX, Ayala Pharmaceuticals, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks therapeutics. Nadia Hindi reports grants, personal fees and non-financial support from PharmaMar, personal fees from Lilly and Tecnopharma, grants from Eisai, and Novartis, outside the submitted work and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen and Daichii-Sankyo. Bruno Vincenzi received research funding (institution) from PharmaMar, Eli Lilly, Deciphera Pharmaceutical; consulting fees (advisory role) from Deciphera Pharmaceuticals, Blueprint Medicines, PharmaMar, Gentili, Eisai, Blueprint Medicines, Boehringer Ingelheim, Abbott, Rain Therapeutics and SpringWorks therapeutics. César Serrano has received research funding (institution) from IDRX, Karyopharm, Pfizer, Inc., Deciphera Pharmaceuticals, and Bayer AG; consulting fees (advisory role) from CogentBio, Immunicum AB, Deciphera Pharmaceuticals and Blueprint Medicines; payment for lectures from PharmaMar, Bayer AG and Blueprint Medicines; and travel grants from Gilead, PharmaMar, Pfizer, Bayer AG, Novartis, and Lilly. David S. Moura reports institutional research grants from PharmaMar, Eisai, Immix BioPharma and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer and Pfizer, and personal fees from Tecnopharma, outside the submitted work. The remaining authors declare no competing interests. Jean-Yves Blay received research funding and honoraria from Bayer, Roche, Deciphera and Blueprint.